Panmira appoints chief executive

Hari Kumar will oversee inflammation portfolio

Panmira Pharmaceuticals, a developer of therapies for inflammatory diseases, based in San Diego, California, US, has appointed Hari Kumar as chief executive.

Until recently, Kumar was chief business officer of Amira Pharmaceuticals and led the transaction with Bristol-Myers Squibb for the sale of Amira's fibrosis programme.

Panmira was spun out of Amira Pharmaceuticals prior to Amira's acquisition by Bristol-Myers Squibb.

Kumar and his team will oversee Panmira's inflammation portfolio, which features a CRTH2 programme. The leading candidate, AM211, has demonstrated inhibition of eosinophils over 24 hours following oral, once-daily dosing in Phase I studies.

The firm says CRTH2 antagonists show promise for several diseases including eosinophilic esophagitis, eosinophilic asthma, COPD, and atopic dermatitis.

You may also like

Research & Development

Lindus Health and Quotient Sciences team up to accelerate drug development process

The pair will provide biotech and pharma sponsors with enhanced patient recruitment for early-stage clinical trials and a direct path from first-in-human to proof-of-concept trials
Research & Development

CAR T-cell therapy shows promise for restoring gut health and intestinal regeneration

Researchers at Cold Spring Harbor Laboratory have demonstrated that anti-uPAR CAR T-cell therapy can clear senescent cells and restore intestinal regeneration, offering a potential new approach to treating age- and radiation-related gut damage
Research & Development

New Osaka-developed reverse genetics system accelerates norovirus vaccine and drug research

Osaka University scientists have created the first simple, efficient system to generate infectious human noroviruses, paving the way for faster antiviral screening and vaccine development
Research & Development

Chemify secures $1.6m Gates Foundation grant to accelerate digital chemistry for tuberculosis drug discovery

The follow-on funding supports Chemify and Lgenia in designing and synthesising new small-molecule candidates for high-priority TB targets using Chemify’s AI-driven digital chemistry platform
Research & Development

GlaxoSmithKline and Oxford BioTherapeutics partner to advance antibody-based therapeutics for cancer

The collaboration leverages OBT's proprietary OGAP-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targets
Research & Development

PLL Therapeutics opens New Zealand subsidiary to accelerate ALS clinical research in Asia-Pacific

The new entity will support Phase II ALS patient recruitment in New Zealand (where incidence rates exceed the global average) and expand PLL Therapeutics’ footprint in the Asia-Pacific neurodegenerative disease research landscape
Manufacturing

Titan Enterprises highly commended for Manufacturer of the Year at industry awards

Recognition reflects the company’s investment in innovation and precision flow measurement
Subscribe now